NOVO-AZITHROMYCIN PEDIATRIC POWDER FOR SUSPENSION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)

Disponible desde:

TEVA CANADA LIMITED

Código ATC:

J01FA10

Designación común internacional (DCI):

AZITHROMYCIN

Dosis:

200MG

formulario farmacéutico:

POWDER FOR SUSPENSION

Composición:

AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 200MG

Vía de administración:

ORAL

Unidades en paquete:

15/22.5ML

tipo de receta:

Prescription

Área terapéutica:

OTHER MACROLIDES

Resumen del producto:

Active ingredient group (AIG) number: 0126072003; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2016-11-28

Ficha técnica

PRODUCT MONOGRAPH
PR
NOVO-AZITHROMYCIN
Azithromycin Tablets 250 mg
Azithromycin (as Azithromycin monohydrate hemiethanolate)
PR
NOVO-AZITHROMYCIN PEDIATRIC
Azithromycin Powder for Oral Suspension
100 mg*/5 mL and 200 mg*/ 5mL
*
Azithromycin (as Azithromycin monohydrate hemiethanolate)
ANTIBIOTIC
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Control No: 198791
Date of Revision:
October 07, 2016
_Novo-Azithromycin Product Monograph _
_ _
_Page 2 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
................................................................................................
5
WARNINGS AND PRECAUTIONS
...............................................................................
5
ADVERSE REACTIONS
..............................................................................................
10
DRUG
INTERACTIONS...............................................................................................
16
DOSAGE AND ADMINISTRATION
...........................................................................
20
OVERDOSAGE
............................................................................................................
25
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 25
STORAGE AND
STABILITY.......................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 28
PART II: SCIENTIFIC INFORMATION
.............................................................................
30
PHARMACEUTICAL INFORMATION
.......................................................................
30
CLINICAL TRIALS
.........................................